Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application

Stock News

09/10

Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the "Acceptance Notice" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.

Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.

This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1185698776"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1185698776\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1185698776?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-10 19:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1185698776","market":"sg","top_or_hot":-1,"title":"Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application","media":"Stock News","content":"<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.<br><br>Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.<br><br>This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Beijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBeijing Centergate Technologies Receives NMPA Acceptance for Ticagrelor Tablets Marketing Application\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-09-10 19:34</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.<br><br>Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.<br><br>This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IPOS","symbol_name":"Renaissance International IPO ETF","start_time":0,"source_url":"","article_id":"1185698776","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1185698776","pubTimestamp":1789040057,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IPOS":"Renaissance International IPO ETF","BK0028":"国家队","BK0239":"医药制造","000931":"中关村","BK0178":"特色小镇","BK0075":"新三板"},"translate_title":"北京盛捷科技替格瑞洛片上市申请获国家药监局受理","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"000931":1,"IPOS":1},"content_text":"Beijing Centergate Technologies (Holding) Co., Ltd. (000931.SZ) has announced that its subsidiary, Duoduo Pharmaceutical Co., Ltd., recently received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA). The marketing authorization application for ticagrelor tablets (specifications: 60mg and 90mg) has been formally accepted.Ticagrelor tablets are intended for use in combination with aspirin in patients with acute coronary syndrome (ACS) or those with a history of myocardial infarction and at least one high-risk factor for atherothrombotic events (as referenced in the PEGASUS clinical trial). The therapy aims to reduce the incidence of cardiovascular death, myocardial infarction, and stroke.This regulatory milestone marks a significant step forward in the company's pharmaceutical pipeline, reinforcing its commitment to expanding therapeutic options for patients with serious cardiovascular conditions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}